Competition authority will investigate price hikes of generic drugsBMJ 2016; 355 doi: https://doi.org/10.1136/bmj.i5849 (Published 01 November 2016) Cite this as: BMJ 2016;355:i5849
- Nigel Hawkes
Companies that made huge increases in the prices the NHS pays for out-of-patent medicines are facing an inquiry by the Competition and Markets Authority (CMA).
The CMA announced the investigation into “suspected unfair pricing by way of charging excessive prices in the supply of certain pharmaceutical products” without naming any of the companies being investigated. But the Times newspaper, which has run a series of investigative stories about generic drug pricing, reported that Concordia International, one of the companies featured in the stories, had confirmed that it was under investigation.1
Concordia, formerly known as AMCo,2 was formed by the private equity …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial